Tchekmedyian V, et al. - In patients with recurrent or metastatic adenoid cystic carcinoma (R/M ACC), researchers performed this phase II trial of lenvatinib (multitargeted tyrosine kinase inhibitor) using a two-stage minimax design. Lenvatinib 24 mg was orally administered every day. The overall response rate was assessed as the primary end point and progression-free survival and safety were secondary end points. This study included 33 patients, of whom 32 were could be evaluated for the primary end point. The prespecified overall response rate primary end point was met, showing the antitumor activity of lenvatinib in R/M ACC patients. Though it required monitoring and management, the observed toxicity with lenvatinib was similar to previous studies.